ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Treatment of Hepatitis C Viral Infection with Novel Direct Acting Antivirals in Kidney Transplant Recipients – Single Center Experience.

K. Hatahet,1 M. Ghanta,1 A. Gillespie,1 I. Lee,1 H. El-Halawany,2 K. Qureshi,2 K. Lau,3 S. Karhadkar,3 A. Di Carlo,3 S. Constantinescu,1 S. Rao.1

1Nephrology, Temple University, Phildelphia, PA
2Hepatology, Temple University, Philadelphia, PA
3Surgery, Temple University, Philadelphia, PA.

Meeting: 2016 American Transplant Congress

Abstract number: 404

Keywords: Graft function, Proteinuria, Rejection

Session Information

Session Name: Concurrent Session: It's Just Not the Donor: Impact of Recipient Factors on Outcomes

Session Type: Concurrent Session

Date: Tuesday, June 14, 2016

Session Time: 2:30pm-4:00pm

 Presentation Time: 3:42pm-3:54pm

Location: Ballroom A

Kidney transplant recipients (KTRs) with Hepatitis C virus infection (HCV+ve) have higher proteinuria and inferior patient and graft survival compared to HCV negative KTRs. Due to high incidence of rejection, interferon (IFN) based regimens are contraindicated in HCV+ve KTRs. Novel direct acting antivirals (DAA) are increasingly utilized for treatment of HCV in general population, with limited data in KTRs.

We studied virologic response, graft function, proteinuria, and acute rejection in 11 HCV+ve KTRs who completed DAA therapy (Rx); 7M:4F, mean age-59+/- 5yrs, AA (73%), diabetes mellitus (73%), hypertension (91%), all had deceased donor KT and were on CNIs, 6 donors were HCV+ve. All patients had detectable HCV viral load (genotype 1A-n=10, genotype 2-n=1) and majority had failed pre-transplant IFN Rx. The median time from KT to initiation of DAA was 13 months (range 6-124 months). DAA regimens utilized were Ledipasvir /Sofosbuvir (73%), Sofosbuvir /Simeprevir (18%) and Ribavirin/Sofosbuvir (9%). DAA Rxs were well tolerated with the exception of dose modification of ribavirin due to anemia.

Majority, 91% (10/11) had sustained virologic response at 12 weeks (SVR12) after completion of DAA Rx. There were no episodes of acute rejection associated with DAA Rx. Serum creatinine (SCr) and spot urine protein/creatinine ratio (Up/c) at 3 and 6 months pre- and post- DAA Rx were analyzed in the 10 patients who achieved SVR12. The mean SCr pre and post DAA Rx was similar (1.4mg/dl). There was a significant reduction in proteinuria, with median U p/c ratio pre-DAA Rx of 0.38mg/g (range 0.05-1.32mg/g) and median U p/c ratio post-DAA Rx of 0.18 mg/g (range 0.05-0.48 mg/g) (p=0.02).

In conclusion, DAA Rxs were highly effective, safe, and well tolerated in HCV+ve KTRs. The graft function remained stable during DAA Rx without any episodes of acute rejection. The decrease in proteinuria associated with SVR could represent the amelioration of HCV-related kidney effects and potentially improve graft survival. Further studies on the impact of successful treatment of HCV+ve KTRs with DAA on post-transplant diabetes, cardiovascular disease, and long term patient survival are warranted.

CITATION INFORMATION: Hatahet K, Ghanta M, Gillespie A, Lee I, El-Halawany H, Qureshi K, Lau K, Karhadkar S, Di Carlo A, Constantinescu S, Rao S. Treatment of Hepatitis C Viral Infection with Novel Direct Acting Antivirals in Kidney Transplant Recipients – Single Center Experience. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Hatahet K, Ghanta M, Gillespie A, Lee I, El-Halawany H, Qureshi K, Lau K, Karhadkar S, Carlo ADi, Constantinescu S, Rao S. Treatment of Hepatitis C Viral Infection with Novel Direct Acting Antivirals in Kidney Transplant Recipients – Single Center Experience. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/treatment-of-hepatitis-c-viral-infection-with-novel-direct-acting-antivirals-in-kidney-transplant-recipients-single-center-experience/. Accessed June 3, 2025.

« Back to 2016 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences